Assessing Quality Gaps and Clinician Perspectives on AI Integration in Colorectal Cancer NGS Pathways
Authors:
- Luxiga ThanabalachandranLTLuxiga Thanabalachandran
- Darya AliDADarya Ali
- Avery Newman-SimmonsANAvery Newman-Simmons
- Claire NormanCNClaire Norman
- Daniel JafariDJDaniel Jafari
- Tamara GrahovacTGTamara Grahovac
- Aaron PollettAPAaron Pollett
- Weei-Yuarn HuangWHWeei-Yuarn Huang
- Lina ChenLCLina Chen
- Shaqil KassamSKShaqil Kassam
- Carly C. BarronCBCarly C. Barron
- Suneil KhannaSKSuneil Khanna
Open Access
- 9 September 2026
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 540
Abstract
Next-generation sequencing (NGS) is integral to colorectal cancer (CRC) care, but its value depends on results being available when treatment decisions are made. We conducted a qualitative study to identify quality gaps in CRC NGS pathways and assess perspectives on digital and artificial intelligence (AI)-enabled workflow support. Semi-structured interviews were conducted with 22 medical oncologists and pathologists from 14 Ontario hospitals, and transcripts were analyzed thematically. Five themes emerged: (1) clinical indications and test ordering, where initiation was inconsistent because of unclear reflex-testing criteria, reliance on upstream clinicians, staging uncertainty, evolving indications, and funding constraints; (2) tissue, pathology, and laboratory workflow, where participants attributed bottlenecks and turnaround variability to send-out testing, staffing, infrastructure, and capacity; (3) interdisciplinary communication and tracking, where informal communication, unclear ownership, and manual tracking highlighted the need for closed-loop confirmation and alerts; (4) reporting and clinical integration, where report clarity, interpretability, and timing affected use; and (5) electronic health record integration and AI integration, where fragmented systems and limited interoperability delayed result access. Participants supported clinician-supervised digital or AI-enabled tools for case identification, triage, tracking, and overdue-result alerts. CRC NGS optimization requires standardized reflex criteria, clearer ownership, closed-loop tracking, reliable routing, structured reporting, and interoperable infrastructure.Keywords
Funding Information
- Pfizer Canada (349589)
- Pfizer Canada (103743675)
This publication has 39 references indexed in Scilit:
- Application of artificial intelligence and digital tools in cancer pathologyThe Lancet Digital Health, 2025
- Low Cholinesterase Is a Potential Poor Prognostic Factor in Colorectal Cancer Presenting With Tumor Markers NegativeCancer Reports, 2025
- Artificial intelligence entering the pathology arena in oncology: current applications and future perspectivesAnnals of Oncology, 2025
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2024
- Preoperative serum cholinesterase as a prognostic factor in patients with colorectal cancerAnnals of Gastroenterological Surgery, 2024
- Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementationESMO Open, 2023
- Detection of Colorectal Adenocarcinoma and Grading Dysplasia on Histopathologic Slides Using Deep LearningThe American Journal of Pathology, 2022
- Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancerCancer Medicine, 2022
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyThe Lancet Oncology, 2022
- Artificial intelligence in digital pathology — new tools for diagnosis and precision oncologyNature Reviews Clinical Oncology, 2019